Therapeutic targets in idiopathic pulmonary fibrosis
- PMID: 28947042
- DOI: 10.1016/j.rmed.2017.07.062
Therapeutic targets in idiopathic pulmonary fibrosis
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal interstitial lung disease. After many drugs failed in clinical trials, improvements in the understanding of the pathogenesis of IPF led to the approval of two drugs that slow the progression of the disease. However, the prognosis for patients with IPF remains poor and the search continues for drugs that inhibit the pathogenic pathways active in IPF to reduce or even halt the progression of the disease. In this article, we review the mechanisms of action of the two approved therapies for IPF (nintedanib and pirfenidone) and of the investigational compounds that are in Phase II trials and discuss the potential for combination therapy in the treatment of IPF.
Keywords: Idiopathic pulmonary fibrosis.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Similar articles
-
Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.BMC Pulm Med. 2016 Mar 3;16:38. doi: 10.1186/s12890-016-0201-9. BMC Pulm Med. 2016. PMID: 26940352 Free PMC article.
-
Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years.Eur Respir J. 2017 Oct 26;50(4):1701209. doi: 10.1183/13993003.01209-2017. Print 2017 Oct. Eur Respir J. 2017. PMID: 29074545 Review.
-
Evaluating new treatment options.Am J Manag Care. 2017 Jul;23(11 Suppl):S183-S190. Am J Manag Care. 2017. PMID: 28978213
-
New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.Am J Respir Crit Care Med. 2014 Oct 15;190(8):867-78. doi: 10.1164/rccm.201403-0509PP. Am J Respir Crit Care Med. 2014. PMID: 25090037 Free PMC article. Review.
-
Update in diffuse parenchymal lung disease, 2013.Am J Respir Crit Care Med. 2015 Feb 1;191(3):270-4. doi: 10.1164/rccm.201405-0856UP. Am J Respir Crit Care Med. 2015. PMID: 25635490 Free PMC article.
Cited by
-
METTL3-mediated m6A RNA methylation induces the differentiation of lung resident mesenchymal stem cells into myofibroblasts via the miR-21/PTEN pathway.Respir Res. 2023 Nov 28;24(1):300. doi: 10.1186/s12931-023-02606-z. Respir Res. 2023. PMID: 38017523 Free PMC article. Review.
-
Natural Product-Based Potential Therapeutic Interventions of Pulmonary Fibrosis.Molecules. 2022 Feb 22;27(5):1481. doi: 10.3390/molecules27051481. Molecules. 2022. PMID: 35268581 Free PMC article. Review.
-
Redox Imbalance in Idiopathic Pulmonary Fibrosis: A Role for Oxidant Cross-Talk Between NADPH Oxidase Enzymes and Mitochondria.Antioxid Redox Signal. 2019 Nov 10;31(14):1092-1115. doi: 10.1089/ars.2019.7742. Epub 2019 Apr 5. Antioxid Redox Signal. 2019. PMID: 30793932 Free PMC article. Review.
-
Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.BMC Pulm Med. 2020 Jan 31;20(1):27. doi: 10.1186/s12890-020-1060-y. BMC Pulm Med. 2020. PMID: 32005219 Free PMC article.
-
Mesenchymal Stem Cells for the Treatment of Idiopathic Pulmonary Fibrosis.Front Med (Lausanne). 2018 May 15;5:142. doi: 10.3389/fmed.2018.00142. eCollection 2018. Front Med (Lausanne). 2018. PMID: 29868594 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
